Medicine Development Leader, Infectious Diseases R&D
Research Triangle Park, North Carolina
Most recent: Medicines Development Leader of cabotegravir (GSK1265744) international project team responsible for all aspects of development of an HIV-1 integrase inhibitor (oral tablet and long-acting parenteral formulation) for HIV treatment and prevention indications.Prior: Leader of international project teams responsible for development of multiple HIV-1 integrase inhibitors leading to marketing approval of dolutegravir (Tivicay). Leader of global development programs for CCR5… Show more Most recent: Medicines Development Leader of cabotegravir (GSK1265744) international project team responsible for all aspects of development of an HIV-1 integrase inhibitor (oral tablet and long-acting parenteral formulation) for HIV treatment and prevention indications.Prior: Leader of international project teams responsible for development of multiple HIV-1 integrase inhibitors leading to marketing approval of dolutegravir (Tivicay). Leader of global development programs for CCR5 antagonist for HIV infection; NRTI portfolio: Trizivir, Combivir, Ziagen, Epivir, Retrovir and Epzicom/Kivexa; genetic-based screening test for abacavir hypersensitivity reaction; and development of HIV-1 protease inhibitor. Show less